[Seite 111↓]

Literatur

[ACOG`02]ACOG Committee on Gynecologic Practice: „The role of the generalist obstetrician-gynecologist in the early detection of ovarian cancer”, Gynecol Oncol 87, S. 237 - 239, 2002

[Akahira`01]Akahira JI, Yoshikawa H, Shimizu Y, Tsunematsu R, Hirakawa T, Kuramoto H, Shiromizu K, Kuzuya K, Kamura T, Kikuchi Y, Kodama S, Yamamoto K, Sato S: „Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study“, Gynecol Oncol 81, S. 398 - 403, 2001

[Allen`99]Allen DG, Coulter J: „Survival of patients with epithelial ovarian cancer and the effect of lymphadenectomy in those with stage 3 disease“, Aust NZ J Obstet Gynecol 39, S. 420 - 424, 1999

[Berek`99]Berek JS, Bertelsen K, du Bois A, Brady MF, et al.: „Advanced epithelial ovarian cancer: 1998 consensus statements”, Annals of Oncology 10 (Suppl. 1), S. 87 - 92, 1999

[du Bois`97]du Bois A, Lück HJ, Meier W, Möbus V, Costa S, Richter B, Bauknecht T, Warm M, Schroeder W, Olbricht S, Nitz U, Jackisch C: „Carboplatin Plus Paclitaxel as First-Line Chemotherapy in Previously Untreated Advanced Ovarian Cancer“, Seminars in Oncology 24 (Suppl. 11), S. 28 - 33, 1997

[du Bois`01]du Bois A, Pfisterer J, Kellermann L, Kreienberg R: „Die Therapie des fortgeschrittenen Ovarialkarzinoms in Deutschland: Welchen Einfluss hat die Teilname an klinischen Studien?“, Geburtshilfe Frauenheilkunde 61, S. 863 - 871, 2001

[du Bois`03]du Bois A: „Primäre Chemotherapie des Ovarialkarzinoms“ in du Bois, Lichtenegger, von Minckwitz, Wallwiener „Taxol-Therapie in der gynäkologischen Onkologie“, W. Zuckschwerdt Verlag München Wien New York, S. 1 – 12, 2003

[du Bois`03-1]du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S et al.: „A randomized clinical trial of cisplatin / paclitaxel versus carboplatin / paclitaxel as first-line treatment of ovarian cancer“, J Natl Cancer Inst 95, S. 1320 – 1329, 2003

[Bridgewater`99]Bridgewater JA, Nelstrop AE, Rustin GJ, Gore ME, McGuire WP, Hoskins WJ: „Comparison of Standard and CA-125 Response Criteria in Patients With Epithelial Ovarian Cancer Treated With Platinum or Paclitaxel“, Journal of Clinical Oncology 17, S. 501 - 508, 1999

[Bristow`02]Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ: „Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta – analysis”, J Clin Oncol 20, S. 1248-1259, 2002

[Bruchim`01]Bruchim I, Altaras M, Fishman A: „Age Contrasts in Clinical Characteristics and Pattern of Care in Patients with Epithelial Ovarian Cancer“,Gynecologic Oncology 86, S. 274 - 278, 2001

[Bühl`99]Bühl A, Zöfel P: „SPSS Version 8 Einführung in die moderne Datenanalyse unter Windows“, Bonn: Addison-Wesley-Longman, 1999


[Seite 112↓]

[Carnino`97]Carnino F, Fuda G, Ciccone G, Iskra L, Guercio E, Dadone D, Conte PF: „Significance of lymph node sampling in epithelial carcinoma of the ovary“, Gynecol Oncol 65, S. 467 -472, 1997

[Cass`01]Cass I, Li AJ, Runowicz CD, Fields AL, Goldberg GL, Leuchter RS, Lagasse LD, Karlan BY: „Pattern of lymph node metastases in clinically unilateral stage I invasive epithelial ovarian carcinomas“, Gynecolgic Oncology 80, S. 56 - 61, 2001

[Chi`99]Chi DS, Venkatraman ES, Masson V, Hoskins WJ: „The Ability of Preoperative Serum CA-125 to Predict Optimal Primary Tumor Cytoreduction in Stage III Epithelial Ovarian Carcinoma”, Gynecologic Oncology 77, S. 227 - 231, 2000

[Chi‘01]Chi D, Liao J, Leon L, Venkatraman E, Hensley M, Bhaskaran D, Hoskins W: „Identification of Prognostic Factors in Advanced Epithelial Ovarian Carcinoma“, Gynecologic Oncology 82, S. 532 - 537, 2001

[Cooper`02]Cooper BC, Sood AK, Davis CS, Ritchie JM, Sorosky JI, Anderson B, Buller RE: „Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer”, Obstet Gynecol 100, S. 59 - 64, 2002

[Covens`02]Covens A, Carey M, Bryson P, Verma S, Kee Fung M, Johnston M: „Systematic Review of First-Line Chemotherapy for Newly Diagnosed Postoperative Patients with Stage II, III, or IV Epithelial Ovarian Cancer”, Gynecologic Oncology 85, S. 71 - 80, 2002

[Cox`72]Cox DR: „Regression Models and life-tables”, JR Stat Soc B 34, S. 187 – 202, 1972

[Cramer`83]Cramer DW, Welch WR, Cassells S, Scully RE: „Mumps, menarche, menopause, and ovarian cancer”, Am J Obstst Gynecol 147, S. 1-6, 1983

[Cramer`99]Cramer DW, Liberman RF, Titus-Ernstoff L, Welch WR, Greenberg ER, Baron JA, Harlow BL: „Genital talc exposure and risk of ovarian cancer”, Int J Cancer 81, S. 351 – 356, 1999

[Curtin´97]Curtin JP, Malik R, Venkatraman ES, Barakat R, Hoskins WJ: „Stage IV Ovarian Cancer: Impact of Surgical Debulking“, Gynecologic Oncology 64, S. 9 - 12, 1997

[Deutsche Krebsgesellschaft`01]Deutsche Krebsgesellschaft EV: „ Kurzgefasste Interdisziplinäre Leitlinien 2002, Diagnostik und Therapie maligner Erkrankungen, Maligne Ovarialtumoren“, W Zuckschwerdt Verlag München, S. 284 - 297, 2001

[Dittrich`96]Dittrich C: „Die medikamentöse Therapie des Ovarialkarzinoms“, Wien-Med-Wochenschr. 146, S. 23 - 33, 1996

[Eisenkop`98]Eisenkop SM, Friedman RL, Wang HJ: „Complete Cytoreductive Surgery Is Feasible and Maximizes Survival in Patients with Advanced Epithelial Ovarian Cancer: A Prospectivve Study“, Gynecologic Oncology 69, S. 103 - 108, 1998

[Eisenkop`00]Eisenkop SM, Friedman RL, Spirtos NM: „The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma”, Cancer 88, S. 144 - 153, 2000


[Seite 113↓]

[Eisenkop‘01]Eisenkop SM, Spirtos NM: „What Are the Current Surgical Objectives, Strategies, and Technical Capabilities of Gynecologic Oncologists Treating Advanced Epithelial Ovarian Cancer?“, Gynecologic Oncology 82, S. 489 - 497, 2001

[Eisenkop’01-1]Eisenkop SM, Spirtos NM: „Procedures Required to Accomplish Complete Cytoreduction of Ovarian Cancer: Is there a Correlation with Biological Aggressiveness and Survival?“, Gynecologic Oncology 82, S. 435 - 441, 2001

[Eisenkop`01-2]Eisenkop SM, Spirtos NM: „The clinical Signifikance of Occult Macroscopically Positive Retroperitoneal Nodes in Patients with Epithelial Ovarian Cancer”, Gynecologic Oncology 82, S. 143 - 149, 2001

[Engel`01]Engel J, Schubert-Fritschle G: „Epidemiologie“ in Kuhn: Manual maligne Ovarialtumoren Empfehlungen zur Diagnostik, Therapie und Nachsorge“, Tumorzentrum München, S. 1 - 9, 2001

[Enomoto`03]Enomoto T, Kuragaki C, Yamasaki M, Sugita N et al.: „Is Clear Cell Carcinoma and Mucinous Carcinoma of the Ovary Sensitive to Combination Chemotherapy with Paclitaxel and Carboplatin?”, 39th ASCO Annual Meeting, Abstract: 1797, 2003

[Fathalla`71]Fathalla MF: „Incessant ovulation-a factor in ovarian neoplasia“, Lancet 2, S. 163, 1971

[Friedman`97]Friedman RL, Eisenkop SM, Wang HJ: „Second-look Laparotomy for Ovarian Cancr Provides Reliable Prognostic Information and Improves Survival“, Gynecologic Oncology 67, S. 88 - 94, 1997

[Folk`95]Folk JJ, Botsford M, Musa AG: „Monitoring cancer antigen 125 levels in induction chemotherapy for epithelial ovarian carcinoma and predicting outcome of second-look procedure“, Gynecol Oncol 57, S. 178 - 182, 1995

[Geisler`96]Geisler JP, Miller GA, Lee TH, Harwood RM, Wiemann MC, Geisler HE: „Relationship of preoperative serum CA-125 to survival in epithelial ovarian carcinoma”, J Reprod Med 41, S. 140 - 142, 1996

[Geisler`96-1]Geisler JP, Wiemenn MC, Miller GA, Geisler HE: „Estrogen and progesterone receptor status as prognostic indicators in patients with optimally cytoreduced stage III c serous cystadenocarcinoma of the ovary”, Gynecol Oncol 60, S. 424 - 427, 1996

[Green`97]Green A, Purdie D, Bain C, Siskind V, Russell P, Quinn M, Ward B: „Tubal sterilisation, hysterectomy and decreased risk of ovarian cancer. Survey of Women`s Health Study Group”, Int J. Cancer 71, S. 948 - 951, 1997

[Gronlund`02]Gronlund B, Hogdall C, Hansen HH, Engelholm SA: „Performance status rather than age is the key prognostic factor in second-line treatment of elderly patients with epithelial ovarian carcinoma”, Cancer 94, S. 1961 - 1967, 2002

[A`Hern`95]A`Hern RP, Gore ME: „Impact of doxorubicin on survival in advanced ovarian cancer”, J Clin Oncol 13, S. 726 - 732, 1995

[Hess`03]Hess V, A`Hern RP; Gore ME: „Relative Platinum – Resistance of Mucinous Carcinoma of the Ovary”, 39th ASCO Annual Meeting, Abstract: 1796, 2003


[Seite 114↓]

[Higgins`99]Higgins RV, Neumann RW, Gardner J, Hall JB: „Is age a barrier to the aggressive treatment of ovarian cancer with paclitaxel and carboplatin?”, Gynecol Oncol 75, S. 464 – 467, 1999

[Holschneider`00]Holschneider CH, Berek JS: „Ovarian Cancer: Epidemiology, Biology, and Prognostic Factors”, Seminars in Surgical Oncology 19, S. 3 – 10, 2000

[Horn`95]Horn IC, Fricke K, Krugmann J: „Histologische Klassifikation und morphologische Prognosefaktoren bei malignen Ovarialtumoren”, Zentralblatt für Gynäkologie 117, S. 335 - 345, 1995

[Hoskins`89]Hoskins WJ, Rubin SC, Dulaney E, Chapman D, Almadrones L, Saigo P, Markman M, Hakes T, Reichman B, Jones WB et al.: „Influence of secondary cytoreduction at the time of second-look laparotomy on the survival of patients with epithelial ovarian carcinoma”, Gynecol Oncol 34, S. 365 - 371, 1989

[Hoskins`94]Hoskins WJ: „Epithelial Ovarian Carcinoma: Principles of Primary Surgery”, Gynecologic Oncology 55, S. 91 - 96, 1994

[Hoskins`94-1]Hoskins WJ, McGuire WP, Brady MF, Homesley HD, Creasman WT, Berman M, Ball H, Berek JS: „The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma”, Am J Obstet Gynecol 170(4), S. 974 - 980, 1994

[Husain`01]Husain A, Chi DS, Prasad M, Abu-Rustum N, Barakat RR, Brown CL, Poynor EA, Hoskins WJ, Curtin JP: „The Role of Laparoscopy in second-Look Evaluations for Ovarian Cancer”, Gynecologic Oncology 80, S. 44 - 47, 2001

[International Collaborative Ovarian Neoplasm Group`02]International Collaborative Ovarian Neoplasm Group: „Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON 3 randomised trial”, Lancet 360, S. 505 -515, 2002

[Irwin`91]Irwin KL, Weiss NS, Lee NC, Peterson HB: „Tubal sterilisation, hysterectomy, and the subsequent occurrence of epithelial ovarian cancer“, Am J Epidemiol 134, S. 362 - 369, 1991

[Jänicke`99]Jänicke F: „Das fortgeschrittene Ovarialkarzinom“, Deutsches Ärzteblatt 96, S. 207 - 214, 1999

[Kaplan`58]Kaplan EL, Meier P: „Nonparametric estimation from incomplete observations“, J Am Statist Assoc 53, S. 457 – 481, 1958

[Kirschbaum`01]Kirschbaum M et al.: „Checkliste Gynäkologie und Geburtshilfe“, Thieme Verlag Stuttgart New York, 2001

[Kommoss`92]Kommoss F, Pfisterer J, Thome M, Schafer W, Sauerbrei W, Pfeiderer A: „Steroid receptors in ovarian carcinoma: immunohistochemical determination may lead to new aspects”, Gynecol Oncol 47, S. 317 – 322, 1992

[Koensgen`02]Koensgen D, Sehouli J, Katsares I, Oskay G, Stengel D, Porzsolt F, Lichtenegger W: „Is quality of life (QOL) a prognostic factor in ovarian cancer?”, 38th ASCO Annual Meeting, Abstract: 2814, 2002


[Seite 115↓]

[Kreienberg`98]Kreienberg R: „Die operative Therapie des Ovarialkarzinoms”, Der Onkologe 4, S. 1123 - 1130, 1998

[Kristensen`97]Kristensen GB, Trope C: „Epithelial ovarian carcinoma“, Lancet 349, S. 113 - 117, 1997

[Kuhn`01]Kuhn W, Hamann U, Rehbock J, Schmalfeldt B, Schwoerer: „Operative Therapie“, in „Kuhn: Manual maligne Ovarialtumoren Empfehlungen zur Diagnostik, Therapie und Nachsorge“, Tumorzentrum München, S. 24 - 31, 2001

[Kuhn`01-1]Kuhn W, du Bois A, Pfisterer J: „Operative Therapie des fortgeschrittenen Ovarialkarzinoms“, Der Gynäkologe 34, S. 1050 - 1057, 2001

[Lambrou`03]Lambrou NC, Bristow RE: „Ovarian cancer in elderly women [In Process Citation]”, Oncology (Huntingt) 17, discussion 1081, S. 1075- 1081, 2003

[Ledermann`03]Ledermann JA: „Randomised Trial of Paclitaxel in Combination with Platinum Chemotherapy versus Platinum-based Chemotherapy in the Teatment of Relapsed Ovarian Cancer (ICON 4 / Ovar 2.2)”, 39th ASCO Annual Meeting, Abstract: 1794, 2003

[Lichtenegger`98]Lichtenegger W, Sehouli J, Buchmann E, Karajanev C, Weidemann H: „Operative results after primary and secondary debulking-operations in advanced ovarian cancer“, J Obstet Gynaecol Res 24, S. 447 - 451, 1998

[Lichtenegger`01]Lichtenegger W, Sehouli J, Buchmann E, Weidemann H: „Das fortgeschrittene Karzinom – Möglichkeiten und Grenzen der operativen Therapie des Ovarialkarzinoms“, in Kindermann G, Dimpfl T: „Berichtsband des 53. Kongresses der DGGG“, Thieme, S. 94 - 98, 2001

[Lippman`88]Lippman SM, Alberts DS, Slymen DJ, Weiner S, Aristizabal SA, Luditch A, Davis JR, Surwit EA: „Second-look laparotomy in epithelial ovarian carcinoma. Prognostic factors associated with survival duration”, Cancer 61, S. 2571 - 2577, 1988

[Lutz`01]Lutz L, Kuhn W, Späthe K: „Chemotherapie“, in Kuhn: „Manual maligne Ovarialtumoren Empfehlungen zur Diagnostik, Therapie und Nachsorge“, Tumorzentrum München, S. 35 - 77, 2001

[Malkasian`84]Malkasian GD, Melton LJ, O`Brien PC, Greene MH: „Prognostic significance of histologic classification and grading of epithelial malignancies of the ovary”, Am J Obstet Gynecol 149, S. 274 – 284, 1984

[Mantel`61]Mantel N: „Evaluation of survival data and two new rank order statistics arising in its considerations“, Cancer Chemother Rep 50, S. 163 - 170, 1966

[Marchetti`02]Marchetti M, Zambon A, Lamaina V, Spadaro M, Marchioro S: „Ultrasound as a possible screening method in ovarian cancer“, Eur J Gynaecol Oncol 23, S. 123 - 126, 2002

[Markman`92]Markman M, Reichman B, Hakes T, Lewis JL, Jones W, Rubin S, Barakat R, Curtin J, Almadrones L, Hoskins W: „Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancer“, J Clin Oncol 10, S. 1479 - 1484, 1992


[Seite 116↓]

[Markman`93] Markman M, Lewis JL, Saigo P, Hakes T, Rubin S, Jones W, Reichman B, Curtin J, Barakat R, Almadrones L, Morrissey T, Hoskins W: „Impact of Age on Survival of Patients with Ovarian Cancer“, Gynecologic Oncology 49, S. 236 - 239, 1993

[Massi`96]Massi D, Susini T, Savino L, Boddi V, Amunni G, Colafranceschi M: „Epithelial ovarian tumors in the reproductive age group”, Cancer 77, S. 1131 - 1136, 1996

[McGuire`96]McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M: „Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer”, N Engl J Med 334, S. 1 - 6, 1996

[McGuire`97]McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M: „Comparison of combination therapy with paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with suboptimal stage III and stage IV ovarian cancer: a Gynecologig Oncology Group study”, Semin Oncol 24 (Suppl. 2), S. 13 - 16, 1997

[Meerpohl`97]Meerpohl HG: „Die Second-look-Operation beim Ovarialkarzinom. Ist eine Neubewertung erforderlich?”, Der Gynäkologe 30, S. 118 - 125, 1997

[Meerpohl`02]Meerpohl HG: „Primäre Therapie des Ovarialkarzinoms” in Sehouli J, Lichtenegger W: „Chemotherapien in der Gynäkologischen Onkolgie“, Akademos, S. 97 - 107, 2002

[Meier`97]Meier W: „Sinnvoller Einsatz der Tumormarker beim Ovarialkarzinom“, Der Gynäkologe 30, S. 133 - 140, 1997

[Menon`00]Menon U, Talaat A, Rosenthal AN, Macdonald ND, Jeyerajah AR, Skates SJ, Sibley K, Oram DH, Jacobs IJ: „Performance of ultrasound as a second line test to serum CA 125 in ovarian cancer screening“, BJOG 107, S. 165 - 169, 2000

[Miller`92]Miller DS, Spirtos NM, Ballon SC, Cox RS, Soriero OM, Teng NN: „Critical reassessment of second-look exploratory laparotomy for epithelial ovarian carcinoma. Minimal diagnostic and therapeutic value in patients with persistent cancer”, Cancer 69, S. 502-510, 1992

[Möbus`97]Möbus V, Volm T, Kreienberg R: „Welche Aussichten ergeben sich durch neuere Chemotherapeutika beim Ovarialkarzinom?“, Der Gynäkologe 30, S. 108 - 117, 1997

[van Nagell`00]van Nagell JR, De Priest PD, Reedy MB, Gallion HH, Ueland FR, Pavlik EJ, Kryscio RJ: „The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer“, Gyncol Oncol 77, S. 350 - 356, 2000

[Narod`01]Narod SA, Sun P, Ghadirian P, Lynch H, Isaacs C, Garber J, Weber B, Karlan B, Fishman D, Rosen B, Tung N, Neuhausen S: „Tubal ligation and risk of ovarian cancer in carriers of BRCA 1 or BRCA 2 mutations: a case-control study“, Lancet 357, S. 1467 - 1470, 2001

[NIH`94]NIH: „National Institutes of Health Consensus Development Conference Statement. Ovarian Cancer: Screening, Treatment, and Follow-up”, Gynecologic Oncology 55, S. 4 - 12, 1994


[Seite 117↓]

[Omura`91]Omura GA, Brady MF, Homesley HD, Yordan E, Major FJ, Buchsbaum HJ, Park RC: „Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience”, J Clin Oncol 9, S. 1138 - 50, 1991

[Opri`01]Opri F: „Second-line Therapie” in Sehouli J, Lichtenegger W: „Chemotherapien in der Gynäkologischen Onkolgie“, Akademos, S. 69 - 82, 2001

[Ozols`02]Ozols RF: „Update on the management of ovarian cancer”, Cancer 8, (Suppl. 1), S. 22 - 30, 2002

[Panici`02]Panici PB, Angioli R: „Role of lymphadenectomy in ovarian cancer”, Best Pract Res Clin Obstet Gynaecol 16, S. 529 – 551, 2002

[Parker`94]Parker D, Bradley C, Bogle SM, Lay J, Masood M, Hancock AK, Naylor B, Price JJ: „Serum albumin and CA 125 are powerful predictors of survival in epithelial ovarian cancer“, Br J Obstet Gynaecol 101, S. 888 - 893, 1994

[Parmar`03]Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM et al.: „Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial”, Lancet 361, S. 2099 – 2106, 2003

[Pecorelli`01]Pecorelli S et al.: „FIGO Annual Report on the Results of Treatment in Gynecologic Cancer. FIGO Committee on Gynecologic Oncology”, Journal of Epidemiology and Biostatistics, 2001

[Pfisterer`02]Pfisterer J, du Bois A: „Das Ovarialkarzinom. Therapeutische Standards – klinische Empfehlungen“, Thieme Verlag Stuttgart New York, 2002

[Pfisterer`03]Pfisterer J: „Müssen wir den Stellenwert und Zeitpunkt der Operation beim Ovarialkarzinom neu definieren?“, in du Bois, Lichtenegger, von Minckwitz, Wallwiener: „Taxol-Therapie in der gynäkologischen Onkologie“, W. Zuckschwerdt Verlag München Wien New York, S. 13 – 21, 2003

[Piccart`00]Piccart MJ, du Bois A, Gore ME, Pecorelli S, Pujade-Lauraine E: „A new standard of care for treatment of ovarian cancer“, European Journal of Cancer 36, S. 10 - 12, 2000

[Piccart`00-1]Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C et al.: „Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in womaen with advanced epithelial ovarian cancer: three-year results”, J Natl Cancer Inst 92, S. 699 - 708, 2000

[De Priest`94]De Priest, Varner E, Powell J, Fried A, Puls L, Higgins R, Shenson D, Kryscio R, Hunter JE, Andrews SJ: „The efficacy of a sonographic morphology index in identifying ovarian cancer: a multi-institutional investigation”, Gynecol Oncol 55, S. 174 - 178, 1994

[Pschyrembel`94]Pschyrembel W, Strauss G, Petri E: „Ginekologia praktyczna“, Wydawnictwo Lekarskie PZWL, 1994

[Puls`96]Puls LE, Duniho T, Hunter JE, Kryscio R, Blackhurst D, Gallion H: „The Prognostic Implication of Ascites in Advanced-Stage Ovarian Cancer”, Gynecologic Oncology 61, S. 109 - 112, 1996

[Quade`02]Quade G: „Prevention of ovarian cancer”, University of Bonn, Medical Center, 2002


[Seite 118↓]

[Rahaman`02]Rahaman J, Cohen C: „Impact of aszites on survival in advanced ovarian cancer38th ASCO Annual Meeting, Abstract: 837, 2002

[Rakar`90]Rakar S, Kovacic J, Cavic M, Lukanovic A, Mozina A: „Prognostic factors in ovarian cancer” , Eur J Gynecol Oncol 11(3), S. 171 - 173, 1990

[di Re`96]di Re F, Baiocchi G, Fontanelli R, Grosso G, Cobellis L, Raspagliesi F, di Re E: „Systematic pelvic and paraaortic lymphadenectomy for advanced ovarian cancer: prognostic significance of node metastases”, Gynecol Oncol 62, S. 360 - 365, 1996

[Reles`97]Reles A, Wein U, Lichtenegger W: „Transvaginal color Doppler sonography and conventional sonography in the preoperative assessment of adnexal masses”, J Clin Ultrasound 25, S. 217 - 25, 1997

[Ricke`03]Ricke J, Sehouli J, Hach C, Hanninen EL, Lichtenegger W, Felix R: „Prospectiv evaluation of contrast-enhanced MRI in the depiction of peritoneal spread in primary or recurrent ovarian cancer”, Eur Radiol 13, S. 943 – 949, 2003

[Riman`98]Riman T, Persson I, Nilsson S: „Hormonal aspects of epithelial ovarian cancer: review of epidemiological evidence”, Clin Endocrinol 49, S. 695 - 707, 1998

[De Rosa`95]De Rosa V, di Mangoni S, Brunetti A, Caraco C, Graziano R, Gallo MS, Maffeo A: „Computed tomography and second-look surgery in ovarian cancer patients. Correlation, actual role and limitations of CT scan”, Eur J Gynecol Oncol 16, S. 123 - 129, 1995

[Rubin`91]Rubin SC, Hoskins WJ, Saigo PE, Chapman D, Hakes TB, Markman M, Reichman B, Almadrones L, Lewis JL: „Prognostic factors for recurrence following negative second-look laparotomy in ovarian cancer patients treated with platinum-based chemotherapy”, Gynecol Oncol 42, S. 137 - 141, 1991

[Rubin`99]Rubin SC, Randall TC, Armstrong KA, Chi DS, Hoskins WJ: „ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings”, Obstet Gynecol 93, S. 21 - 24, 1999

[Sakurai`02]Sakurai S, Shimizu Y, Utsugi K, Umezawa S, Kato T, Fukasawa I, Inaba N, Hasumi K: „Validity of complete paraaortic and pelvic lymphadenectomy in apparent stage I (pT1) ovarian carcinoma”, 38th ASCO Annual Meeting, Abstract: 801, 2002

[Scarabelli`95]Scarabelli C, Gallo A, Zarrelli A, Visentin C, Campagnutta E: „Systematic pelvic and para-aortic lymphadenectomy during cytoreductive surgery in advanced ovarian cancer: potential benefit on survival”, Gynecol Oncol 56, S. 328 - 227, 1995

[Scharf`02]Scharf A, Günter HH, S Sohn: „Screening auf Ovarialkarzinom”, Der Gynäkologe 35, S. 537 - 547, 2002

[Schelling`01]Schelling M, de Waal JC: „Früherkennung”, in Kuhn: „Manual maligne Ovarialtumoren Empfehlungen zur Diagnostik, Therapie und Nachsorge“, Tumorzentrum München, S. 10 - 13, 2001

[Schelling`01-1]Schelling M, de Waal JC: „Präoperative Diagnostik, Diagnosesicherung“, in Kuhn: „Manual maligne Ovarialtumoren Empfehlungen zur Diagnostik, Therapie und Nachsorge“, Tumorzentrum München, S. 14 - 15, 2001


[Seite 119↓]

[Schildkraut`00]Schildkraut JM, Halabi S, Bastos E, Marchbanks PA, McDonald JA, Berchuck A: „Prognostic Factors in Early-Onset Epithelial Ovarian Cancer: A Population-Based Study“, Obstet Gynecol 95, S. 119 - 127, 2000

[Schmalfeldt`01]Schmalfeldt B, Diebold J, Harbeck N, Kuhn W, Nathrath W: „Prognosefaktoren”, in Kuhn: „Manual maligne Ovarialtumoren Empfehlungen zur Diagnostik, Therapie und Nachsorge“, Tumorzentrum München, S. 21 - 23, 2001

[Schmidt-Matthiesen`02]Schmidt-Matthiesen H, Bastert G, Wallwiener D: „Gynäkologische Onkologie. Diagnostik, Therapie und Nachsorge auf der Basis der AGO-Leitlinien“, Schattauer Stuttgart New York, S. 73 – 96, 2002

[Schneider`98]Schneider D, Halperin R, Halperin D, Bukovsky I, Hadas E: „Prediction of the survival of patients with advanced ovarian cancer according to a risk model based on a scoring system“, Eur J Gynaecol Oncol 19, S. 547 - 552, 1998

[Schwartz`95]Schwartz PE, Chambers JT, Taylor KJ: „Early detection and screening for ovarian cancer”, J Cell Biochem Suppl 23, S. 233 - 237, 1995

[Scully`99]Scully RE, Sobin LH: „World Health Organisation (WHO). International histological classification of tumours. Histological typing of ovarian tumors”, Springer Berlin Heidelberg, 1999

[Scully`00]Scully RE: „Influence of origin of ovarian cancer on efficacy of screening“, The Lancet 355, S. 1028 – 1029, 2002

[Sehouli`01]Sehouli J: „Ovarialkarzinom First-line Therapie“, in Sehouli J, Lichtenegger W: „Chemotherapien in der Gynäkologischen Onkolgie“, Akademos, S. 59 - 68, 2001

[Sehouli’02]Sehouli J, Stengel D, Elling D, Ortmann O, Blohmer J, Riess H, Lichtenegger W: „First-Line Chemotherapy with Weekly Paclitaxel and Carboplatin for Advanced Ovarian Cancer: Phase I Study“, Gynecologic Oncology 85, S. 321 - 326, 2002

[Sehouli`02-1]Sehouli J, Stengel D, Drzewiecki K, Beldermann F, Camara O, Dari J et al.: „Weekly Taxol and Carboplatin as first-line Therapie in advanced ovarian cancer: a phase II-study”, 38th ASCO Annual Meeting, Abstract: 811, 2002

[Sehouli`02-2]Sehouli J, Lichtenegger W: „Neue Daten zum rezidivierten Ovarialkarzinom“, in Sehouli J, Lichtenegger W: „Chemotherapien in der Gynäkologischen Onkolgie“, Akademos, S. 109 - 115, 2002

[Sehouli`02-3]Sehouli J, Stengel D, Oskay G, Camara O, Hindenburg HJ, Klare P, Blohmer J, Heinrich G, Elling D, Ledwon P, Lichtenegger W: „A Phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy“, Ann Oncol 13, S. 1749 - 1755, 2002

[Sehouli`03] Sehouli J, Akdogan Z, Heinze T, Konsgen D, Stengel D, Mustea A, Lichtenegger W: „Preoperative determination of CASA (Cancer Associated Serum Antigen) and CA-125 for the discrimination between benign and malignant pelvic tumor mass: a prospective study”, Anticancer Res 23, S. 1115-1118, 2003


[Seite 120↓]

[Sehouli`03-1]Sehouli J, Könsgen D, Klapp c, Walle U, Katsares I, Oskay G, Mustea A, Bühling K, Lichtenegger W: „Lebensqualität in der gynäkologischen Onkologie – Ein Bericht mit den Ergebnissen des ASCO-Meetings 2002“, Geburtsh Frauenheilk 63, S. 752 – 757, 2003

[Sehouli`03-2]Sehouli J, Könsgen D, Mustea A, Oskay-Özcelik G, Katsares I, Weidemann H, Lichtenegger W: „IMO – intraoperatives Mapping des Ovarialkarzinom“, Zentralbl Gynäkol 125, S. 129 – 135, 2003

[Sehouli`03-3]Sehouli J, Lichtenegger W: „Kommentar zur Publikation: International Collaborative Ovarian Neoplasm Group: Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON 3 randomised trial. Lancet 2002 Aug 17; 360(9332):505-15”, Gyn 8, S. 196 -197, 2003

[Shimizu`98]Shimizu Y, Kamoi S, Amada S, Akiyama F, Silverberg SG: „Toward the development of a universal grading system for ovarian epithelial carcinoma: Testing of a proposed system in a series of 461 patients with uniform treatment and follow-up”, Cancer 82, S. 893 – 901, 1998

[Sliutz`96]Sliutz G: „Prognosefaktoren beim Ovarialkarzinom”, Wien-Med-Wochenschr. 146, S. 14 - 17, 1996

[Stadel`75]Stadel BV: „The etiology and prevention of ovarian cancer“, American Journal of Obstetrics and Gynecology 123, S. 772 – 774, 1975

[Stegner`96]Stegner HE: „Gynäkologie und Geburtshilfe”, Ferdinand Enke Verlag Stuttgart, 1996

[Stiff`00]Stiff PJ, Veum-Stone J, Lazarus HM, Ayash L, Edwards JR, Keating A, Klein JP, Oblon DJ, Shea TC, Thome S, Horowitz MM: „High-dose chemotherapy and autologous stemm-cell transplantation for ovarian cancer: an autologous blood and marrow transplant registry report“, Ann Intern Med 133, S. 504 - 515, 2000

[Tattersall`02]Tattersall M: „Ovarian cancer chemotherapy: carboplatin as standard“, Lancet 360, S. 500 - 501, 2002

[Taylor`99]Taylor AE, Olver IN, Sivanthan T, Chi M, Purnell C: „Observer error in grading performance status in cancer patients“, Supportive Care in Cancer 7, S. 332 - 335, 1999

[Thigpen`93]Thigpen T, Brady MF, Omura GA, Creasman WT, McGuire WP, Hoskins WJ, Williams S: „Age as prognostic factor in ovarian carcinoma”, Cancer 71, S. 606 - 614, 1993

[Thomssen`02]Thomssen C, Meier W: „Rezidivchirurgie beim Ovarialkarzinom. Indikationen und Möglichkeiten“, Der Onkologe 8, S. 1216 - 1221, 2002

[Trimble`01]Trimble EL: „Prospects for improving staging of ovarian cancers”, Lancet357, S. 159 - 160, 2001

[UICC`94]UICC, Hossfeld DK, Sherman CD, Love RR, Bosch FX: „Podrecznik onkologii klinicznej”, Wydawnictwo Naukowe PWN Warszawa Krakow, 1994

[UICC`97]UICC, Sobin LH, Wittekind C: „TNM Classification of malignant tumors”, Wiley-Liss New York, 1997

[Verres`92]Verres R: „Die Kunst zu leben. Krebsrisiko und Psyche“, Piper München Zurüch, 1992


[Seite 121↓]

[Wagner`01]Wagner U, Blohmer JU, Lück HJ: „Medikamentöse Rezidivtherapie“, Der Gynäkologe 34, S. 1020 - 1023, 2001

[West`97]West RJ, Zweig SF: „Meta-analysis of chemotherapy regimens for ovarian carcinoma: a reassessment of cisplatin, cyclophosphamide and doxorubicin versus cisplatin and cyclophosphamide”, Eur J Gynaecol Oncol 18, S. 343 - 348, 1997


© Die inhaltliche Zusammenstellung und Aufmachung dieser Publikation sowie die elektronische Verarbeitung sind urheberrechtlich geschützt. Jede Verwertung, die nicht ausdrücklich vom Urheberrechtsgesetz zugelassen ist, bedarf der vorherigen Zustimmung. Das gilt insbesondere für die Vervielfältigung, die Bearbeitung und Einspeicherung und Verarbeitung in elektronische Systeme.
DiML DTD Version 4.0Zertifizierter Dokumentenserver
der Humboldt-Universität zu Berlin
HTML-Version erstellt am:
20.05.2005